We are live on !
Find out more
Polaris Capital Management Portfolio holdings
AUM
$953M
Turnover
8.99%
1-Year Est. Return
27.74%
This Fund
S&P 500
This Quarter Est. Return
-1.47%
1 Year Est. Return
+27.74%
3 Year Est. Return
+94.41%
5 Year Est. Return
+112.23%
10 Year Est. Return
+328.01%
AUM
$953M
AUM Growth
-$108M
(-10%)
Cap. Flow
-$72.5M
Cap. Flow % of AUM
Cap. Flow %
-7.61%
Top 10 Holdings %
Top 10 Hldgs %
48.9%
Holding
89
New
5
Increased
7
Reduced
52
Closed
3
Avg Time Held
4.4
years
Top 10 Avg Time Held
2.9
years
Top 20 Avg Time Held
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$18.9M |
| 2 |
Genpact
G
|
+$18.3M |
| 3 |
Cytokinetics
CYTK
|
+$6.04M |
| 4 |
Limbach Holdings
LMB
|
+$2.63M |
| 5 |
Waystar Holding Corp
WAY
|
+$2.25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Webster Financial
WBS
|
+$21.1M |
| 2 |
Gilead Sciences
GILD
|
+$19.4M |
| 3 |
Nomad Foods
NOMD
|
+$12.7M |
| 4 |
Smurfit Westrock
SW
|
+$6.72M |
| 5 |
Eastman Chemical
EMN
|
+$6.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 28.2% |
| 2 | Healthcare | 26.51% |
| 3 | Consumer Discretionary | 11.8% |
| 4 | Technology | 9.15% |
| 5 | Materials | 7.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Popular Inc
BPOP
$10.1B
| $78.8M | 8.27% |
506,941
-22,300
| -4% | -$3.77M |
2016 Q3
40 quarters
|
|
2
Jazz Pharmaceuticals
JAZZ
$13.9B
| $74.2M | 7.78% |
320,466
-8,500
| -3% | -$2.1M |
2021 Q2
21 quarters
|
|
|
3
Smurfit Westrock
SW
$22.3B
| $65.7M | 6.89% |
1,490,202
-145,600
| -9% | -$6.72M |
2024 Q4
7 quarters
|
|
4
Linde
LIN
$235B
| $47.4M | 4.97% |
99,816
+100
| +0.1% | +$49.1K |
2019 Q4
27 quarters
|
|
5
Arrow Electronics
ARW
$10.7B
| $41.8M | 4.39% |
184,200
-11,500
| -6% | -$2.44M |
2020 Q1
26 quarters
|
|
6
Lantheus
LNTH
$6.54B
| $39.4M | 4.13% |
395,900
-28,600
| -7% | -$2.92M |
2025 Q3
4 quarters
|
|
7
Marathon Petroleum
MPC
$129B
| $34.2M | 3.59% |
86,482
-7,000
| -7% | -$2.42M |
2014 Q4
47 quarters
|
|
8
CVS Health
CVS
$121B
| $29.6M | 3.11% |
345,600
-19,600
| -5% | -$1.92M |
2020 Q4
23 quarters
|
|
9
JPMorgan Chase
JPM
$894B
| $28.6M | 3% |
86,391
-3,900
| -4% | -$1.36M |
2016 Q3
40 quarters
|
|
10
United Therapeutics
UTHR
$25.1B
| $26.5M | 2.78% |
48,950
-4,500
| -8% | -$2.33M |
2021 Q1
22 quarters
|
|
11
SLM Corp
SLM
$4.09B
| $23.3M | 2.45% |
1,030,800
-46,900
| -4% | -$1.21M |
2022 Q1
18 quarters
|
|
|
12
Cytokinetics
CYTK
$8.67B
| $22.8M | 2.39% |
346,100
+79,200
| +30% | +$6.04M |
2026 Q2
1 quarter
|
|
13
Ingredion
INGR
$6.13B
| $20.9M | 2.2% |
218,600
-7,700
| -3% | -$779K |
2020 Q3
24 quarters
|
|
14
International Bancshares
IBOC
$4.18B
| $20.9M | 2.19% |
305,400
-15,700
| -5% | -$1.15M |
2014 Q4
47 quarters
|
|
15
Cullen/Frost Bankers
CFR
$9.8B
| $19.1M | 2.01% |
125,300
-8,000
| -6% | -$1.29M |
2023 Q2
13 quarters
|
|
|
16
Regeneron Pharmaceuticals
REGN
$84.3B
| $19M | 1.99% |
+25,040
| New | +$18.9M |
2026 Q3
0 quarters
|
|
17
Adobe
ADBE
$105B
| $18.3M | 1.92% |
76,160
-6,040
| -7% | -$1.51M |
2026 Q2
1 quarter
|
|
18
Allison Transmission
ALSN
$9.05B
| $17.6M | 1.85% |
155,600
-9,300
| -6% | -$1.12M |
2021 Q4
19 quarters
|
|
|
19
Genpact
G
$6.99B
| $17.6M | 1.85% |
+541,200
| New | +$18.3M |
2026 Q3
0 quarters
|
|
20
AbbVie
ABBV
$504B
| $17.4M | 1.82% |
66,394
-4,870
| -7% | -$1.25M |
2020 Q2
25 quarters
|
|
21
Booking.com
BKNG
$121B
| $17M | 1.78% |
104,200
-7,810
| -7% | -$1.47M |
2026 Q2
1 quarter
|
|
22
Chubb
CB
$140B
| $16.7M | 1.76% |
51,458
-3,580
| -7% | -$1.24M |
2016 Q1
42 quarters
|
|
23
Elevance Health
ELV
$96.6B
| $16M | 1.68% |
41,124
-2,700
| -6% | -$1.08M |
2014 Q4
47 quarters
|
|
|
24
Eastman Chemical
EMN
$7.47B
| $15.9M | 1.67% |
245,300
-95,000
| -28% | -$6.62M |
2026 Q1
2 quarters
|
|
25
General Dynamics
GD
$94.9B
| $15.7M | 1.64% |
47,227
-2,700
| -5% | -$1M |
2014 Q4
47 quarters
|
|
Similar funds
Polaris Capital Management's Q3 2026 Portfolio in Review
As of Q3 2026, Polaris Capital Management held 89 positions worth $953M, down 10% from $1.06B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Polaris Capital Management withdrew a net $72.5M in Q3 2026, closing 3 positions and reducing 52 holdings. Its most notable exit was Webster Financial, an estimated $21.1M position sold in full.
By sector, the portfolio is most concentrated in Financials at 28% of assets, down from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Polaris Capital Management opened a new position in Regeneron Pharmaceuticals worth $19M.
- Polaris Capital Management's largest Q3 2026 buy was Regeneron Pharmaceuticals: 25,040 shares worth $19M.
- Polaris Capital Management added most to Cytokinetics in Q3 2026, an estimated $6.04M increase.
- Polaris Capital Management's biggest Q3 2026 reduction was Nomad Foods, cutting an estimated $12.7M.
- Polaris Capital Management fully exited Webster Financial in Q3 2026, selling an estimated $21.1M.
- Polaris Capital Management's ten largest holdings make up 49% of its $953M portfolio in Q3 2026.
- Polaris Capital Management opened 5 new positions and closed 3 in Q3 2026.
- Polaris Capital Management's portfolio value fell 10% quarter-over-quarter to $953M.
Based on Polaris Capital Management's 13F filing for Q3 2026, filed 21 Oct 2026.